Brief: Jiangsu Recbio Technology Says Acceptance Of Clinical Trial Application
26/07/2023 15:38
July 26 (Reuters) - Jiangsu Recbio Technology 2179.HK :
* ACCEPTANCE OF CLINICAL TRIAL APPLICATION FOR NOVEL
ADJUVANTED
RECOMBINANT- SHINGLES VACCINE REC610 IN CHINA
Further company coverage: 2179.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jiangsu Recbio Technology
See all newsBrief: Jiangsu Recbio Technology To Re-Plan Timetable For HPV Vaccine Marketing Application
Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
Brief: Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
Brief: Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of Application Materials For Issuance Of Shares